As on Thursday, Lilly(Eli) & Co (NYSE: LLY) started slowly as it slid -3.76% to $1032.97, before settling in for the price of $1073.29 at the close. Taking a more long-term approach, LLY posted a 52-week range of $623.78-$1133.95.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 18.77%. Meanwhile, its Annual Earning per share during the time was 18.77%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 82.80%. This publicly-traded company’s shares outstanding now amounts to $945.84 million, simultaneously with a float of $851.56 million. The organization now has a market capitalization sitting at $976.55 billion.
Lilly(Eli) & Co (LLY) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – General industry. Lilly(Eli) & Co’s current insider ownership accounts for 9.92%, in contrast to 73.12% institutional ownership. According to the most recent insider trade that took place on Jan 07 ’26, this organization’s 10% Owner sold 292,148 shares at the rate of 1103.48, making the entire transaction reach 322,380,730 in total value, affecting insider ownership by 91,896,978. Preceding that transaction, on Jan 05 ’26, Company’s 10% Owner sold 1,390 for 1085.01, making the whole transaction’s value amount to 1,508,165. This particular insider is now the holder of 92,189,126 in total.
Lilly(Eli) & Co (LLY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 7.49 per share during the current fiscal year.
Lilly(Eli) & Co’s EPS increase for this current 12-month fiscal period is 82.80% and is forecasted to reach 32.72 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 46.12% through the next 5 years, which can be compared against the 18.77% growth it accomplished over the previous five years trading on the market.
Lilly(Eli) & Co (NYSE: LLY) Trading Performance Indicators
Let’s observe the current performance indicators for Lilly(Eli) & Co (LLY). It’s Quick Ratio in the last reported quarter now stands at 1.24. Alongside those numbers, its PE Ratio stands at $51.09, and its Beta score is 0.39. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.43. Similarly, its price to free cash flow for trailing twelve months is now 105.32.
In the same vein, LLY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 20.22, a figure that is expected to reach 7.20 in the next quarter, and analysts are predicting that it will be 32.72 at the market close of one year from today.
